Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

Overview

Journal Immunity

Publisher Cell Press

Specialty Allergy & Immunology

Date 2016 May 19

PMID 27192565

Citations 1082

Authors

Ana C Anderson

Nicole Joller

Vijay K Kuchroo

Affiliations

Soon will be listed here.

Abstract

Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T cell responses and have proven to be effective targets in the setting of chronic diseases where constitutive co-inhibitory receptor expression on T cells dampens effector T cell responses. Unfortunately, many patients still fail to respond to therapies that target CTLA-4 and PD-1. The next wave of co-inhibitory receptor targets that are being explored in clinical trials include Lag-3, Tim-3, and TIGIT. These receptors, although they belong to the same class of receptors as PD-1 and CTLA-4, exhibit unique functions, especially at tissue sites where they regulate distinct aspects of immunity. Increased understanding of the specialized functions of these receptors will inform the rational application of therapies that target these receptors to the clinic.

Citing Articles

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.

Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.

PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.

Co-expression of B7-H3 and LAG3 represents cytotoxicity of CD4 T cells in humans.

Tamura Y, Ohki S, Nagai H, Yoshizato R, Nishi S, Jin Y Front Immunol. 2025; 16:1560383.

PMID: 40070836 PMC: 11893609. DOI: 10.3389/fimmu.2025.1560383.

Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer.

Vo M, Nguyen V, Tran V, Oh H, Jung S, Bae W Cancer Immunol Immunother. 2025; 74(4):143.

PMID: 40056167 PMC: 11890499. DOI: 10.1007/s00262-025-03997-2.

Tumor-intrinsic PRMT5 upregulates FGL1 methylating TCF12 to inhibit CD8 T-cell-mediated antitumor immunity in liver cancer.

Sun J, Yuan H, Sun L, Zhao L, Wang Y, Hou C Acta Pharm Sin B. 2025; 15(1):188-204.

PMID: 40041915 PMC: 11873606. DOI: 10.1016/j.apsb.2024.10.016.

References

G Casado J, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I . Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother. 2009; 58(9):1517-26. PMC: 11030684. DOI: 10.1007/s00262-009-0682-y. View

Monney L, Sabatos C, Gaglia J, Ryu A, Waldner H, Chernova T . Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415(6871):536-41. DOI: 10.1038/415536a. View

Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F . CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995; 25(9):2718-21. DOI: 10.1002/eji.1830250949. View

Wu W, Shi Y, Li J, Chen F, Chen Z, Zheng M . Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. Virol J. 2011; 8:113. PMC: 3061941. DOI: 10.1186/1743-422X-8-113. View

Welch M, Teijaro J, Lewicki H, Colonna M, Oldstone M . CD8 T cell defect of TNF-α and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. Virology. 2012; 429(2):163-70. PMC: 3571684. DOI: 10.1016/j.virol.2012.04.006. View

Davidson D, Schraven B, Veillette A . PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes. Mol Cell Biol. 2007; 27(5):1960-73. PMC: 1820463. DOI: 10.1128/MCB.01983-06. View

Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M . Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009; 113(16):3821-30. DOI: 10.1182/blood-2008-10-185884. View

Chauvin J, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C . TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. J Clin Invest. 2015; 125(5):2046-58. PMC: 4463210. DOI: 10.1172/JCI80445. View

Huang Y, Zhu C, Kondo Y, Anderson A, Gandhi A, Russell A . CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2014; 517(7534):386-90. PMC: 4297519. DOI: 10.1038/nature13848. View

10.

Jha V, Workman C, McGaha T, Li L, Vas J, Vignali D . Lymphocyte Activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity. PLoS One. 2014; 9(8):e104484. PMC: 4133201. DOI: 10.1371/journal.pone.0104484. View

11.

Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S . Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med. 2008; 205(13):2959-64. PMC: 2605241. DOI: 10.1084/jem.20081611. View

12.

Hannier S, Tournier M, Bismuth G, Triebel F . CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. 1998; 161(8):4058-65. View

13.

Stengel K, Harden-Bowles K, Yu X, Rouge L, Yin J, Comps-Agrar L . Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A. 2012; 109(14):5399-404. PMC: 3325733. DOI: 10.1073/pnas.1120606109. View

14.

Boivin N, Baillargeon J, Doss P, Roy A, Rangachari M . Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells. PLoS One. 2015; 10(4):e0124802. PMC: 4401451. DOI: 10.1371/journal.pone.0124802. View

15.

Koguchi K, Anderson D, Yang L, OConnor K, Kuchroo V, Hafler D . Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006; 203(6):1413-8. PMC: 2118310. DOI: 10.1084/jem.20060210. View

16.

Golden-Mason L, Palmer B, Kassam N, Townshend-Bulson L, Livingston S, McMahon B . Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol. 2009; 83(18):9122-30. PMC: 2738247. DOI: 10.1128/JVI.00639-09. View

17.

Santiago C, Ballesteros A, Tami C, Martinez-Munoz L, Kaplan G, Casasnovas J . Structures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. Immunity. 2007; 26(3):299-310. PMC: 7111020. DOI: 10.1016/j.immuni.2007.01.014. View

18.

Gupta S, Thornley T, Gao W, Larocca R, Turka L, Kuchroo V . Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J Clin Invest. 2012; 122(7):2395-404. PMC: 3386804. DOI: 10.1172/JCI45138. View

19.

Pires da Silva I, Gallois A, Jimenez-Baranda S, Khan S, Anderson A, Kuchroo V . Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014; 2(5):410-22. PMC: 4046278. DOI: 10.1158/2326-6066.CIR-13-0171. View

20.

Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T . Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010; 107(17):7875-80. PMC: 2867907. DOI: 10.1073/pnas.1003345107. View